SCHEMBL27291464

SCHEMBL27291464

C=C(Cc1nc(-c2ccc(OCCCC)cn2)no1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ ACACB O00763 1/20 0.41
▸ ACACA Q13085 1/20 0.41
▸ TP53 P04637 2/20 0.40
▸ MITF O75030 1/20 0.40
▸ NCOA3 Q9Y6Q9 1/20 0.40
▸ HCAR2 Q8TDS4 1/20 0.40
▸ RAB9A P51151 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ PLA2G4B P0C869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31707540 0.86 ACACB (0.38) NPC1SMN1; SMN2ALDH1A1NPSR1ACACB
SCHEMBL23578433 0.86 ACACB (0.57) NPC1SMN1; SMN2ALDH1A1ACACBACACA
SCHEMBL27291563 0.83 GSTP1 (0.41) ACACBACACATP53MITFNCOA3
SCHEMBL23578438 0.82 ACACB (0.64) NPC1ACACBACACATP53MITF
SCHEMBL27291369 0.81 MITF (0.43) NPC1SMN1; SMN2ACACBACACATP53
SCHEMBL23588315 0.78 TP53 (0.50) ALDH1A1ACACBACACATP53MITF
SCHEMBL23578251 0.78 MAPT (0.45) SMN1; SMN2ALDH1A1TP53KDM4EMAPT
SCHEMBL30880252 0.76 ACACB (0.56) NPC1SMN1; SMN2ACACBACACATP53
SCHEMBL23578421 0.76 MITF (0.41) TP53MITFNCOA3
SCHEMBL23588172 0.76 TDP1 (0.50) MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4634167-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE Sitryx Therapeutics Limited (GB) 2025-10-22 — — EP disclosed
WO-2024127030-A1 SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE SITRYX THERAPEUTICS LIMITED (GB) 2024-06-20 — — WO disclosed
Send feedback